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ABSTRACT
Tyrosine kinase inhibitors, affecting angiogenesis, have shown therapeutic 
efficacy in renal cell carcinoma (RCC). The increased overall survival is not fully 
explained by their anti-tumor activity, since these drugs frequently induce disease 
stabilization rather than regression. RCC patients frequently develop cachectic 
syndrome. We used the RXF393 human renal carcinoma xenograft that recapitulates 
the characteristics of the disease, including the growth in the mouse kidney 
(orthotopic implantation), and the induction of cachexia with subsequent premature 
death. Sunitinib prevents body weight loss and muscle wasting and significantly 
improves the survival of RXF393-bearing nude mice. The anti-cachectic effect was 
not associated to direct anti-tumor activity of the drug. Most relevant is the ability 
of sunitinib to reverse the cachectic phenotype and rescue the animals from the 
loss of fat tissue. Body weight loss is prevented also in mice bearing the C26 colon 
carcinoma, classically reported to induce cachexia in immunocompetent mice. Among 
the mechanisms, we herein show that sunitinib is able to restrain the overactivation 
of STAT3 and MuRF-1 pathways, involved in enhanced muscle protein catabolism 
during cancer cachexia. 
We suggest that off-target effects of angiogenesis inhibitors targeting STAT3 
are worth considering as a therapeutic option for patients who develop cachexia, 
independently of their anti-tumor activity. 
INTRODUCTION 
Cachexia is a dramatic wasting syndrome associated 
with several chronic diseases, including cancer, and 
primarily involves loss of muscle mass [1]. Cancer 
cachexia affects up to 80% of cancer patients and causes 
reduced physical function, low tolerance to anti-cancer 
therapy and shorter survival [1, 2]. Muscle wasting 
results from excess of protein catabolism over synthesis 
and during cancer it is triggered by increased levels of 
proinflammatory cytokines [3, 4]. Given the complexity 
of this syndrome, progress in the treatment of cancer 
cachexia has been slow. Cancer cachexia is an important 
unmet medical need for which multimodal management is 
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normally aimed at the best supportive care [5, 6].
Patients afflicted by renal cell carcinoma (RCC) 
frequently develop cachexia [7]. This syndrome is believed 
to be caused by the secretion of cytokines or hormones 
from the tumor or the immune system [8]. Tumor-specific 
growth factors, like vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor (PDGF), are 
also highly secreted by RCC [8]. In the past five years, 
the introduction of targeted anti-angiogenic therapy has 
dramatically enlarged the number of therapeutic options 
for the treatment of RCC and significantly improved the 
prospects for patients [9]. 
Sunitinib is a multi-targeted receptor tyrosine kinase 
inhibitor (TKI) that mainly targets VEGF and PDGF 
receptors and it was the first oral TKI to gain regulatory 
approval in this setting [10]. Sunitinib is the reference 
standard of care, recommended in international guidelines 
for the first-line treatment of favorable- or intermediate-
risk RCC [11]. The range of agents available for the 
treatment of RCC has expanded substantially, including 
sorafenib, temsirolimus, everolimus, bevacizumab 
in combination with interferon-α and, more recently, 
pazopanib and axitinib [12]. However, while increasing 
overall survival, these targeted drugs frequently induce 
only disease stabilization. Since survival benefits in RCC 
patients do not always correlate with tumor response, 
other unknown mechanisms may account for the clinical 
benefits. 
In the present study, we show that mice bearing 
RCC-derived RXF393 develop cachexia (i.e. body weight 
loss), which is prevented and/or reversed upon treatment 
with sunitinib, resulting in increased survival. Both muscle 
and fat tissues undergo wasting in RXF393-bearing mice 
and sunitinib is able to prevent the loss of both. This 
unprecedented therapeutic effect is not associated with 
its anti-tumor activity and involves prevention of STAT3 
activation and MuRF-1 over-expression in muscles. As a 
consequence, STAT3 inhibitors should be worth evaluating 
as a therapeutic option for cancer patients who develop 
cachexia. 
RESULTS
Sunitinib prevents RXF393-induced cachexia 
The human renal carcinoma RXF393 transplanted 
in nude mice forms a rapidly growing tumor causing 
progressive body weight loss (BWL), typical of the 
cachectic syndrome. As shown in Figure 1A, all RXF393-
bearing mice rapidly lost weight (a hallmark of cachexia) 
around 15 days after subcutaneous tumor transplantation, 
when tumor weight (TW) was about 700 mg, and died 
shortly after. A significant inverse correlation was observed 
between tumor and body weight (R=-0.941, P<0.001). 
When tumor-bearing mice were treated with sunitinib, 
the inverse correlation between tumor and body weight 
was lost, but it was rapidly restored when treatment was 
interrupted (Fig.1B). Sunitinib treatment (started at about 
100 mg of TW) had a moderate, but significant anti-tumor 
effect (T/C 30%) (Fig.1C, left). All the RXF393-bearing 
mice treated with vehicle developed cachexia (BWL > 
20%) and ought to be killed within 23 days after tumor 
transplantation (Fig.1C, middle), whereas the overall 
survival (time of sacrifice) of sunitinib-treated mice was 
significantly higher (MST 51 days; ILS 250%) (Fig.1C, 
right) and, surprisingly, the tumor reached the maximal 
ethically accepted weight (< 2000mg) without causing 
cachexia. At autopsy, subcutaneous tumors harvested 
from sunitinib-treated mice showed a pale phenotype, 
compared to the highly vascularized appearance of the 
vehicle-treated tumors, consistent with the anti-vascular 
activity of sunitinib (Fig.1C, inserts). Immunohistological 
analysis confirmed the lower vessel density in sunitinib-
treated tumors (data not shown).
To exclude that the anti-cachectic effects of sunitinib 
depends on its effect on tumor growth, we compared the 
therapeutic active dose of sunitinib (40mg/kg) to sub-
optimal doses (20 and 10mg/kg) in RXF393-bearing 
mice. As shown in Fig.1D, left, 40mg/kg inhibited tumor 
growth, while doses of 20mg/kg or 10mg/kg did not exert 
anti-tumor effects. However, a dose-response effect on 
BWL was observed: 10mg/kg delayed BWL by four days 
and 20mg/kg was able to preserve body mass (Fig.1D, 
right). These results suggest that the effect on cachexia 
by sunitinib involves mechanisms aside from inhibition of 
angiogenesis and tumor growth.
To confirm the anti-cachectic effects of sunitinib 
in a more relevant setting, RXF393 was transplanted 
orthotopically in the kidney of nude mice (Fig.2). Tumor-
bearing mice started losing body weight in three weeks 
(Fig.2A), and were to be sacrificed (MST 30 days, Fig.2B) 
when their tumorgrafts reached about 600 mg (Fig.2C), 
because of clear signs of discomfort (i.e. kyphosis, 
immobility, tremor; 20% of BWL). In contrast, sunitinib-
treated mice lived significantly longer (MST 51 days; ILS 
70%, Fig.2B) and no sign of BWL was observed when 
mice were sacrificed with a tumor mass of approx. >1g, 
(Fig.2A and C). At autopsy, tumors growing in the kidney 
of sunitinib-treated mice had a pale phenotype, consistent 
with the drug’s activity (Fig.2C).
Sunitinib prevents RXF393-induced muscle 
wasting
One of the key features of cancer-induced wasting 
syndrome is the loss of skeletal muscle mass [13]. To test 
whether cachexia was accompanied by skeletal muscle 
atrophy, and whether sunitinib prevented this, mice 
bearing subcutaneous RXF393 were treated with sunitinib 
or vehicle and muscle wasting was analyzed at autopsy. 
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To exclude differences due to the tumor burden, RXF393-
bearing mice from vehicle- and sunitinib-treated groups 
were sacrificed when tumor reached comparable sizes. 
Comparable tumor weights (about 400mg) were 
associated to significant BWL in vehicle-treated mice, 
whereas the body weight of sunitinib-treated ones were 
undistinguishable from age- and sex-matched healthy 
mice (tumor-free) (Fig.3A). After death, heart, tibialis 
anterior (TA) and gastrocnemius muscles were collected 
and weighed. In RXF393-bearing mice, no loss of heart 
weight was observed both in vehicle- and sunitinib-
treated mice (Fig.3B) compared to healthy mice, while the 
weight of TA and gastrocnemius muscles from vehicle-
treated ones decreased by about 25% (Fig.3C). Strikingly, 
the mean weight of both muscles from sunitinib-treated 
mice did not significantly differ from that of healthy 
mice, indicating that sunitinib completely protects from 
RXF393-induced muscle wasting (Fig.3C). Moreover, the 
cross-sectional area (CSA) of the TA myofibers showed a 
significant reduction between vehicle-treated and healthy 
animals  (1122 μm2 and 1789 μm2, respectively), which 
was partially but significantly restored upon sunitinib 
treatment (1432 μm2) (Fig.3D, left). Accordingly, 
electron microscopy ultra-structural analysis of the TA 
muscles of healthy mice showed the expected cross-
sectional organization of thin and thick filaments in 
myofibrils, surrounded by mitochondria and cisternae 
of the sarcoplasmic reticulum. Conversely, cachectic 
muscles from tumor-bearing mice showed derangement 
and degeneration of both types of filaments, while 
Figure 1: RXF393-induced cachexia is prevented by sunitinib treatment independently from tumor inhibition. A, 
RXF393 cells were injected subcutaneously into the flank of nude mice: tumor and body weight are plotted over time and their correlation 
is shown. B, RXF393-bearing mice were randomized (TW 120 mg, n=7/group) to receive sunitinib (40 mg/kg, p.o.) daily for the indicated 
time (arrows): tumor and body weights are reported and their correlation is shown. C, RXF393-bearing mice were randomized (TW 120 
mg, n=7/group) to receive sunitinib or vehicle daily for the indicated time (arrows). Tumor weights (left panel) and representative images 
(inserts) of the gross appearance of treated and untreated tumors, excised when mice were euthanized, are shown. Body weights are plotted 
over time (middle panel). Mice treated with sunitinib or not were sacrificed when they lost 20% of body weight and/or showed signs of 
distress (loss of mobility, kyphosis, tremor). Survival curves are depicted (right panel). D, RXF393-bearing mice were randomized (TW 
150 mg, n=9/group) to receive vehicle or sunitinib at the doses of 10, 20 or 40mg/kg daily p.o. The effects of sunitinib on tumor growth (left 
panel) and BW (right panel) are reported. Open arrow=treatment starts, full arrow=treatment ends, red arrow=day of inversion.
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mitochondria and sarcoplasmic reticulum retained their 
normal morphology. Interestingly, treatment of cachectic 
mice with sunitinib reversed the abnormal morphology 
of TA, restoring the normal architecture of sarcomeres 
(Fig.3D, right).
Sunitinib prevents C26-induced cachexia
The beneficial effects of sunitinib were further 
confirmed in another experimental model fully 
characterized for cancer cachexia and previously used to 
study anti-cachexia interventions: the murine C26 colon 
carcinoma [14].
As expected, the C26 tumor induced about 5% BWL 
already 11 days after transplantation and, when BWL 
reached 20%, it led to death 90% of the vehicle-treated 
mice within 15 days (Fig.4A). Likewise RXF393 model, 
there was a significant inverse correlation between tumor 
and body weight (R=-0.9, P<0.05) (Fig.4A). 
Sunitinib only minimally inhibited the tumor growth 
(T/C 69%) (Fig.4B), but it significantly delayed the BWL 
compared to vehicle-treated mice (Fig.4C, left). However, 
when the treatment was interrupted at day 20, all the mice 
previously treated with sunitinib lost weight and were 
terminally euthanized within one week (Fig.4C).
To exclude that the lower BWL in sunitinib-treated 
mice was caused by smaller tumors due to treatment, we 
compared mice bearing tumors of similar size (about 
280 mg), irrespectively of the time after transplantation 
and found that the body weight of sunitinib-treated was 
significantly higher than that of vehicle-treated mice 
(Fig.4D). 
Figure 2: Cachexia is prevented by sunitinib treatment in the RXF393 orthotopic model. RXF393 cells were injected 
orthotopically into the right kidney of nude mice and growing tumors were treated with sunitinib (40 mg/kg, p.o.) or vehicle daily for the 
indicated time (n=9/group). A, Body weights are plotted over time. B, Mice treated with sunitinib or not were sacrificed when they lost 20% 
of body weight and/or showed signs of distress (loss of mobility, kyphosis, tremor) and survival curves are shown. C, Tumor weights were 
determined at sacrifice and median is reported. Range day of sacrifice is reported in brackets. Representative images of the gross appearance 
of treated and untreated tumors growing in the kidney are shown in the inserts. Open arrow=treatment starts, full arrow=treatment ends.
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Sunitinib reverses RXF393-induced cachexia
To test the ability of sunitinib to reverse the wasting 
syndrome once established, mice bearing RXF393 and 
developing cachexia were randomized to receive sunitinib 
or vehicle, when BWL was around 10% (14 days after 
tumor implantation). As shown in Fig.5A, sunitinib 
completely and rapidly reversed BWL even when 
treatment started with larger tumors (about 600-700 mg, 
Fig.5B). The recovery in body weight was accompanied 
by a gain in fat tissue, as shown by micro-CT (computed 
tomography) scans of the entire abdominal region of 
tumor-bearing mice treated with sunitinib (Fig.5C and D, 
day 24). Vehicle-treated mice lost fat tissue concomitantly 
to BWL (day 16). As expected, soon after suspension of 
sunitinib treatment, mice started to lose weight (Fig.5A) 
and fat tissue (Fig.5C, day 33) at a level comparable to 
untreated mice. Of note, body mass was not significantly 
affected in tumor-free mice treated or not with sunitinib 
(data not shown). Altogether, these data show that 
sunitinib treatment exerts its effects, such as preservation 
of body mass and fat tissue, as long as its administration 
is maintained, and even if cachexia has already advanced. 
Figure 3: Sunitinib prevents RXF393-induced skeletal muscle wasting. RXF393-bearing mice were randomized (TW 120 
mg, n=7/group) to receive sunitinib (40 mg/kg p.o.) or vehicle daily. Animals were sacrificed at tumor sizes of about 400mg, and bodies 
(A), hearts (B), TA and gastrocnemius muscles (C) were weighed. D, The effects of treatment on the TA muscles were also determined by 
quantitation of the CSA. Representative ultrastructural images by electron microscopy, showing the morphology of the TA in the various 
conditions are provided. Results are plotted as mean ±SD. n.s.=not significant. 
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Figure 4: Sunitinib prevents C26-induced cachexia. A, C26 cells (1x106) were inoculated subcutaneously in the upper right flank 
of BALB/c mice. Tumor and body weight are plotted over time and their correlation is shown. B-C, C26-bearing mice were randomized 
(TW 100 mg) to receive sunitinib (40 mg/kg, p.o.) or vehicle (n=12 /group) daily for the indicated time; tumor growth (B) and body weight 
(C) are reported. Open arrow = treatment starts, full arrow = treatment ends. D, Body weight of animals with tumors at the same size 
(approx. 280 mg, irrespectively of the time after tumor transplantation) (n=7/group) is reported. Median tumor weight and day with range 
are reported.
Figure 5: Sunitinib reverses RXF393-induced cachexia. Mice bearing subcutaneously RXF393 were randomized with a cachectic 
phenotype, (10% BWL and initial signs of discomfort) and treated with sunitinib (40mg/kg p.o.) or vehicle daily for two weeks (n=7-9/
group). A-B, The effects of sunitinib on body and tumor weights are shown in A and B, respectively. C-D, The effect of sunitinib on fat 
content was determined by micro-CT scan. A quantitation of abdominal fat at the indicated times is reported (C). Data are plotted as 
mean±SD (n=5). Representative images from mice at randomization or from vehicle- or sunitinib-treated mice are shown and the fat tissue 
is highlighted in red (D). Open arrow=treatment starts, full arrow=treatment ends, red arrows=day of CT analysis. 
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Sunitinib prevents MuRF-1 and STAT3 activation 
in muscle of RXF393-bearing mice 
Loss of skeletal muscle mass is generally due 
to reduced protein synthesis, increased degradation or 
a relative imbalance of the two [3, 4]. The molecular 
pathways implicated in these mechanisms were 
investigated in TA muscles of vehicle- and sunitinib-
treated mice. The Muscle RING Finger 1 protein (MuRF-
1), a muscle-restricted ubiquitin ligase involved in the 
accelerated protein degradation during various kinds of 
muscle atrophy [15], was found highly up-regulated in 
muscles from cachectic RXF393-bearing mice, while 
sunitinib treatment was able to prevent MuRF-1 up-
regulation (Fig.6A). More prolonged sunitinib treatment 
led to down-regulation of atrogin-1, another muscle-
specific ubiquitin ligase triggering muscle atrophy [15, 
16], although the effect was less evident. Levels of 
p-AKT over total AKT, usually considered as index of 
protein synthesis, were also evaluated, but not significant 
difference was detected (data not shown).
An important mediator implicated in the 
development of cancer cachexia is the transcription 
factor STAT3 that previous work has shown activated by 
circulating pro-inflammatory cytokines (i.e. IL-6) [17]. 
Muscles from cachectic RXF393-bearing mice exhibited 
over-activation of STAT3, as shown by higher levels of 
phosphorylated STAT3 (p-STAT3) compared to non-
cachectic ones (analyzed at randomization) (Fig.6B). 
Sunitinib inhibited p-STAT3 of muscles from RXF393-
bearing mice at levels comparable to non-cachectic mice. 
Similar results were obtained with sorafenib, 
another multitargeted TKI, also used for the treatment of 
renal cancer [18]. Administration of sorafenib prevented 
the body and muscle weight loss in RXF393-bearing mice 
and this was associated with the inhibition of STAT3 and 
Figure 6: Skeletal muscle wasting is prevented by sunitinib through inhibition of MuRF-1 and p-STAT3. A-B, Tibialis 
anterior muscles of untreated or sunitinib-treated mice (after 9 (9t) or 16 (16t) days of treatments) were analyzed by Western Blot for 
MuRF-1, atrogin-1 (A), p-STAT3 and STAT3 (B) protein levels. Tibialis anterior of non-cachectic mice, sacrificed at randomization, were 
chosen as reference (indicated as Random). GAPDH was used as internal loading control. Densitometric analysis was performed and 
quantitation of protein levels is provided. Results are plotted as mean ±SD. 
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MuRF-1 pathways in TA muscles (Supplementary Fig.1). 
IL-6 was elevated in plasma of mice bearing 
RXF393 or C26, but sunitinib did not change its levels in 
neither model (Supplementary Fig.2), suggesting that the 
effect of sunitinib is not mediated by the direct attenuation 
of this circulating cytokine.
Overall, these data indicate that RXF393-bearing 
mice offer a unique model to test drugs against cancer 
cachexia and that sunitinib, as well as sorafenib, can 
prevent cachexia in vivo by lowering protein catabolism 
through inhibition of STAT3/MuRF-1 activation at least 
in muscles.
DISCUSSION
Renal cell carcinoma is one of the malignancies 
that mostly causes a cancer-associated systemic syndrome 
(i.e. cachexia), mainly consisting in progressive loss 
of the body energy stores and likely reflecting the high 
production of cytokines and growth factors [7, 8]. 
Herein, we report that treatment with sunitinib (and 
sorafenib, Supplementary data) prolonged the survival 
of mice bearing the human kidney carcinoma RXF393, 
transplanted either ectopically in the subcutis or 
orthotopically in the kidney (i.e. mimicking the site of 
tumor origin), by blocking the BWL (i.e. muscle and fat 
wasting) caused by cancer growth. 
Unexpected was the ability of sunitinib to reverse 
the cachectic phenotype once established. In fact, sunitinib 
reversed BWL and rescued the animal from the loss of 
abdominal fat tissue. The anti-cachectic effects of sunitinib 
are not associated to reduced tumor growth, as revealed by 
the prevention of cachexia also at sub-optimal doses of 
sunitinib that did not inhibit tumor growth. Importantly, 
BWL was prevented also in a syngeneic tumor model, the 
C26 colon cancer, classically reported to induce cachexia 
in immunocompetent mice [19]. This shows that such 
anti-cachectic effect also occurs with an intact immune 
system and, furthermore, implies that it is not restricted 
to a single tumor model. These results might explain 
the clinical evidence that often targeted drugs, including 
sunitinib, increase overall survival of RCC patients, 
without inducing tumor shrinkage, but rather causing 
disease stabilization [18, 20].
Of note, during human RCC both cancer and 
subsequent kidney dysfunction may account for the 
cachectic appearance, further accelerating muscle loss 
[21]. Our data, showing similar rates of BWL in mice 
bearing a tumor subcutaneously or orthotopically in the 
kidney, possibly exclude that kidney failure may worsen 
the RXF393-related cachexia.
We have investigated the anti-cachectic effect 
exerted by sunitinib not only at the macroscopic level 
of multiple tissues (fat, heart and skeletal muscles) but 
also at the ultrastructural level in skeletal muscle (i.e. the 
most affected tissue in cancer cachexia). Surprisingly, 
we observed that sunitinib not only was able to spare 
the  muscle mass but even the misalignment of myofibers 
induced by cancer progression. As reported by Aulino 
and coworkers [19] in C26-bearing mice, we report that 
cachectic muscles from RXF393 mice display an aberrant 
distribution of thin and thick filaments that may be due 
to selective degradation of muscle proteins [22]; these 
aberrations can be prevented by sunitinib, allowing 
preservation of muscle mass and probably of its function. 
Decreased protein synthesis and increased 
proteolysis are among the mechanisms leading to muscle 
loss [3]. During atrophy, MuRF-1 and atrogin-1 are 
the crucial muscle-specific ubiquitin ligases that direct 
the polyubiquitination of proteins to target them for 
proteolysis by the 26S proteasome, mediating sarcomeric 
breakdown (MuRF-1, which degrades myosins) [23] 
or shifting gene expression towards a less myogenic 
phenotype (atrogin-1, which degrades MyoD) [24]. Our 
results indicate that cachexia prevention by sunitinib is 
mainly determined by the reduction of proteolysis, rather 
than increased synthesis, as shown by suppression of 
MuRF-1 and, though less evident, atrogin-1 induction and 
unchanged levels of p-AKT/AKT ratio. Since FoxO3 is a 
master transcription factor driving muscle wasting by up-
regulating both MuRF-1 and atrogin-1 [25, 26], we have 
also measured the levels of p-FoxO3 over total FoxO3 in 
the vehicle and sunitinib-treated muscles, but no difference 
was detected. Instead, our data suggest that improvement 
of cachexia is associated to STAT3 inhibition in muscles 
by sunitinib. 
Cancer cachexia is triggered by increased systemic 
inflammation, where pro-inflammatory cytokines (e.g. IL-
6) play a major role [27]. Previous reports demonstrated 
that STAT3 activation induced by IL-6 is per se sufficient 
to induce muscle fiber wasting in vitro as well as in vivo 
and that STAT3 inhibition would abolish skeletal muscle 
wasting downstream of IL-6 in cancer cachexia models 
[17, 28]. Interestingly, STAT3 has been found activated 
also in wasting muscles from patients suffering from 
chronic kidney disease [29] and very recently involved in 
the control of satellite cell expansion and muscle repair 
[30]. Moreover, the IL-6/STAT3 pathway has been also 
implied in increased lipolysis of C26-bearing mice [31], 
thus suggesting that in our experimental models sunitinib 
may spare fat and muscle tissues through similar targets. 
We found that circulating IL-6 was elevated in both nude 
mice bearing RXF393 and in immunocompetent mice 
bearing C26, (as described by others [32, 33]), but was 
not reduced by sunitinib (Supplementary Fig.2). This 
indicates that the anti-cachectic effect of sunitinib is not 
due to reduced circulating IL-6 or that the inhibitory 
target of sunitinib is downstream of the IL-6 cascade (i.e. 
JAK) [17]. Similar results were found upon treatment of 
cachectic rodents with anti-myostatin inhibitors, where 
signs of cachexia were reversed without affecting IL-6 or 
TNF-α plasma levels [32].
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The RXF393 xenograft model secretes high levels of 
VEGF, likely enough to cause a cachectic syndrome [34, 
35]. Indeed, Cao et coworkers have shown that systemic 
treatment with anti-VEGF agents reversed VEGF-induced 
cancer associated systemic syndrome and prolonged 
mouse survival [34]. Surprisingly, antibodies anti-VEGF 
(bevacizumab) or anti-VEGF receptor 2 (DC101) did not 
protect RXF393-carrying mice from cachexia to the same 
extent as sunitinib (data not shown). Presumably, other 
cytokines or growth factors are responsible for cachexia 
in our tumor model.
Although our understanding of cancer cachexia has 
improved dramatically in the past few years, guidelines for 
the prevention and treatment of cancer-related cachexia 
are lacking. New treatments with myostatin inhibitors, 
thalidomide, selective COX-2 inhibitors, ghrelin mimetics 
and selective androgen receptor modulators have shown 
promising results, but their efficacy need to be confirmed 
in clinical trials that are at present testing multimodal 
interventions against cancer cachexia [5, 6]. 
Overall, we show that TKIs, such as sunitinib, 
prevent BWL and preserve muscle and fat tissue, by 
inhibiting STAT3 phosphorylation. STAT3 has been 
identified as a novel tumor target and several inhibitors 
are under development [36]. Only very recently, its 
pharmacological inhibition has been shown to be 
beneficial against cancer cachexia in experimental models 
[37]. Our results further encourage to regard STAT3 
inhibitors as therapeutic option for cancer patients who 
develop cachexia, independently of their direct anti-tumor 
activity.
MATERIAL AND METHODS
Cell lines 
RXF393 (VHL-WT) kidney carcinoma cell line 
[33], was obtained from the NCI Tumor Repository and 
cultured in RPMI1640 (Gibco) with 10% FBS (Sigma 
Aldrich). Authentication of the cell line was done using 
the AmpFlSTR® Identifiler® PCR Amplification Kit 
(Applied Biosystems). Murine C26 colon cancer cells 
[19] were a kind gift of Mario Paolo Colombo (IRCCS-
Istituto Nazionale dei Tumori, Milan) and cultured in 
DMEM high glucose (Gibco) with 10% FBS and 1mM 
L-glutamine (Gibco). Stocks of the cell lines were stored 
frozen in liquid nitrogen, and kept in culture for no more 
than six passages before injection in mice.
Mice and tumor models
RXF393 cells were injected subcutaneously (s.c., 
1.5x106 cells) into the flank or orthotopically (1x105 cells) 
into the right kidney of six- to eight-week-old female 
NCr-nu/nu mice (Harlan), as previously described [38]. 
Nude mice were maintained under specific pathogen-free 
conditions and handled using aseptic procedures. C26 
cells (1x106) were inoculated s.c. in the upper right flank 
of male BALB/c mice (Harlan).
Tumor growth s.c. was measured twice a week with 
Vernier Caliper and plotted as mean tumor weight  (±SE) 
against days after tumor transplantation. The efficacy of 
treatment was expressed as best tumor growth inhibition 
[%T/C = (median weight of treated tumors/median weight 
of control tumors) × 100]. In the orthotopic model, tumor 
appearance was checked twice a week by palpation. 
Cachexia was followed by recording body weight  that 
was plotted as the mean (±SE) against days after tumor 
transplantation. Mice were sacrificed when BWL reached 
> 20% and/or the animals showed clear signs of distress 
(ruffled fur for BALB/c mice, tremor, loss of mobility, 
kyphosis), however with a tumor burden < 2 g. Survival 
day was the time at which mice were euthanized. 
The increment of life span (ILS) was calculated as 
100x[(median survival day of treated mice – median 
survival day of vehicle treated mice)/ median survival day 
of vehicle treated]. Animal study management and data 
collection were done with the Study Director 1.8 software 
(Studylog System, Inc., San Francisco, USA) connected to 
a digital caliper and an electronic balance.
Procedures involving animals and their care were 
conducted in conformity with institutional guidelines 
in compliance  with national (Legislative Decree n. 
26, March 4, 2014; Authorization n.19/2008-A issued 
March 6, 2008, by the Italian Ministry of Health) and 
international laws and policies (EEC Council Directive 
2010/63, August 6, 2013; Standards for the Care and Use 
of Laboratory Animals, U.S. National Research Council, 
Statement of Compliance A5023-01, October 28, 2008), 
and in line with Guidelines for the welfare and use of 
animals in cancer research [39]. 
Drugs and reagents
Sunitinib (Chemietek) was dissolved in methocel 
0.5% and further diluted in saline solution immediately 
before use. It was administered daily orally by gavage at 
the dose of 40mg/Kg, unless otherwise indicated. 
Micro-CT analysis
Mice were anesthetized with a continuous flow 
of 3% isoflurane/oxygen mixture and positioned prone 
with both legs at right angles. The region spanning the 
entire torso to the distal tibia of each mouse was scanned 
with Explore Locus micro-CT scanner (GE Healthcare) 
without contrast agents. Micro-CT projections of the 
animals were acquired using 80 kV, 450 μA current, with 
100 ms acquisition time. Four hundred projections were 
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acquired over 360°. The resolution of the acquired images 
was 93 μm. The reconstructed 3D images were visualized 
and analyzed using MicroView analysis software (GE 
Healthcare).
The amount of adipose tissue was determined 
as described by Luu et al.[40]. Briefly, the gray-scale 
histogram of the reconstructed images presents a peak that 
indicates the presence of fat. A low and a high gray-scale 
threshold corresponding to that peak were chosen. The fat 
was quantified as the sum of the volumes of all the voxels 
with a gray-scale value ranging between the low and the 
high thresholds. The analysis was done on the abdominal 
region (between the proximal end of L1 and the distal end 
of S1).
Electron microscopy
Tibialis Anterior muscles from control, untreated 
and sunitinib-treated mice were excised at sacrifice, cut 
in the sagittal plane with a razor blade and fixed with 
4% paraformaldehyde (PFA) and 2% glutaraldehyde 
in phosphate buffer 0.12 M, pH 7.4 for 2 hours at 4°C, 
followed by incubation at room temperature for 2h in 
OsO4. After dehydration, tissue samples were cleared 
in propylene oxide, embedded in epoxy medium (Epon 
812 Fluka) and polymerized at 60°C for 72 h. From each 
sample, ultrathin (60 nm thick) sections of areas of interest 
were obtained, counterstained with uranyl acetate and lead 
citrate, and examined with an Energy Filter Transmission 
Electron Microscope (EFTEM, ZEISS LIBRA® 120) 
equipped with a YAG scintillator slow-scan CCD camera.
Muscle fiber cross-sectional area measurements
Eight-µm depth cross-sectional tissue sections from 
the TA muscle were fixed in cold acetone, stained with 
hematoxylin and eosin solutions (Fluka) and digitally 
imaged with a CKX41 microscope (Olympus). For each 
muscle, at least 8 randomly selected 20X magnification 
images were quantified with CellF software (Olympus). 
Western Blot analysis
Proteins from TA muscles were extracted with a 
lysis buffer supplemented with proteases inhibitor cocktail 
(Roche), quantitated by BCA Protein or Coomassie 
Plus Assay Kit (Pierce), separated by SDS-PAGE and 
transferred to a PVDF membrane (Millipore). Membranes 
were probed with mouse anti-MuRF-1 (1:30), rabbit anti-
atrogin-1 (1:2000, a kind gift of Dr. S. Lecker from Beth 
Israel Deaconess Medical Center in Boston, USA), rabbit 
anti-phospho STAT3 (Tyr705, 1:2000, Cell Signaling), 
mouse anti-STAT3 (1:1000, Cell Signaling) and mouse 
anti-GAPDH (1:40000, Sigma Aldrich) antibodies. The 
signal was detected with CDP-Star® Substrate (Life 
Technologies). The MuRF-1 antibody was raised against 
rat MuRF-1, as previously described [15].
Statistical analysis
Statistical analyses were done using Prism Software 
(GraphPad Prism 5.01). Differences in survival were 
analyzed by the log-rank test. Correlation was assessed 
by a standard Pearson correlation, after the symmetry 
of the distribution was assured with Skewness and 
Kurtosis. Differences among groups of non-time-related 
measurements were assessed by one-way ANOVA 
followed by the Bonferroni post-test.
In the figures, significance is indicated as follows: * 
P<0.05, ** P<0.01, *** P<0.001.
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